Analysts Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Price Target at $53.67

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the sixteen ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $53.67.

A number of analysts recently commented on the company. Leerink Partnrs lowered IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 5th. Wedbush reaffirmed an "outperform" rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Leerink Partners cut shares of IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $41.00 to $27.00 in a research report on Tuesday, November 5th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Finally, Oppenheimer reiterated an "outperform" rating and set a $53.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, October 29th.

IDEAYA Biosciences Stock Down 4.0 %

Shares of IDEAYA Biosciences stock traded down $0.96 during trading on Tuesday, reaching $23.00. 480,332 shares of the stock were exchanged, compared to its average volume of 831,421. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -9.87 and a beta of 0.82. IDEAYA Biosciences has a 1 year low of $22.10 and a 1 year high of $47.74. The stock's fifty day moving average is $25.02 and its 200 day moving average is $30.83.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same period in the previous year, the firm posted ($0.46) earnings per share. Equities analysts forecast that IDEAYA Biosciences will post -2.45 earnings per share for the current year.

Institutional Trading of IDEAYA Biosciences

Large investors have recently made changes to their positions in the stock. Allworth Financial LP boosted its stake in shares of IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company's stock worth $29,000 after buying an additional 800 shares during the last quarter. Covestor Ltd increased its position in shares of IDEAYA Biosciences by 23,050.0% during the 3rd quarter. Covestor Ltd now owns 926 shares of the company's stock valued at $29,000 after purchasing an additional 922 shares during the last quarter. R Squared Ltd purchased a new position in shares of IDEAYA Biosciences in the fourth quarter worth approximately $35,000. US Bancorp DE boosted its holdings in shares of IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company's stock worth $54,000 after buying an additional 689 shares during the last quarter. Finally, KBC Group NV raised its position in IDEAYA Biosciences by 29.1% in the third quarter. KBC Group NV now owns 2,274 shares of the company's stock worth $72,000 after acquiring an additional 513 shares during the period. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.